Characterization of erythropoietin dimerization

Area of Science:

• Biochemistry
• Protein Chemistry
• Pharmaceutical Sciences

Background:

• Recombinant human erythropoietin (rHuEPO) is a therapeutic glycoprotein hormone.
• Storage under non-ideal conditions can lead to rHuEPO dimerization and aggregation.
• Understanding the dimerization mechanism is critical for product stability and efficacy.

Purpose of the Study:

• To elucidate the molecular mechanism of rHuEPO dimerization.
• To identify the specific sites and bonds involved in dimer formation.
• To provide insights for developing strategies to prevent rHuEPO aggregation.

Main Methods:

• Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS) for molecular mass determination.
• Endoproteinase LysC peptide mapping to identify structural changes.
• N-terminal sequencing to characterize the dimer interface.
• Fluorescent thiol probe assay to detect free thiols.

Main Results:

• rHuEPO dimer has an average molecular mass of 53.5 kDa, approximately double the monomer (27.8 kDa).
• LysC mapping revealed new peptide peaks in the dimer, indicating specific cleavage sites.
• Sequencing identified two types of EPO dimers, suggesting a complex formation pathway.
• The mechanism involves reduction of the Cys7-Cys161 disulfide bond followed by random reoxidation.

Conclusions:

• The primary mechanism for rHuEPO dimerization involves disulfide bond reduction and subsequent intermolecular reoxidation.
• Aggregation to higher molecular weight species results from random intermolecular reoxidation of Cys7 and Cys161.
• These findings are essential for improving the stability and shelf-life of rHuEPO therapeutics.